3 курс / Фармакология / Эндоназальные кортикостероиды
.pdf40.Drettner B. (1988) Therapeutic aspects of sinusitis in relation to pathogenesis. Acta Otolaryngol 1988;458(Suppl):13.
41.Drouin, J., et al., (1992) Homodimer formation is rate-limiting for high affinity DNA binding by glucocorticoid receptor. Mol Endocrinol., 6, 1299-1309 (1992).
42.Druce H.M. (1990) Adjuncts to medical management of sinusitis. Otolaryngol Head Neck Surg 1990;103:880 –3.
43.Edelman DA, van Os WAA. (1996) Safety of intranasal beclomethasone dipropionate: a review. Respir Care 1996;11:1025-1030.
44.Fakhri S., Frenkiel S., Hamid Q.A. (2002) Current views on the molecular biology of chronic sinusitis. J Otolaryngol. 2002 Aug;31 Suppl 1:S2-9.
45.Fiocchi A., Hughes S., Medley H.V. (1999) Effects of inhaled and intranasal corticosteriods on growth velocity in children; a comparison of fluticasone propionate with beclomethasone dipropionate. Eur Respir J 1999;14 Suppl 30:13S.
46.Foggia D., Christensen J. (2004) Sinusitis/Rhinosinusitis Guidelines 2004, Health Plan of Nevada. Assessed in Internet: “2004 14.26 Sinusitis-rhinosinusitis Guidelines.pdf”.
47.Fokkens W. (2004) An update on acute rhinosinusitis management. “Responding to challenge of polyposis and rhinosinusitis. EAACI Congress,Amsterdam, June 13, 2004. The abstract book”. P. 12-16.
48.Fokkens W., Scadding K, Baker RC, Richards DH. (1998) Fluticasone propionate in the treatment of rhinitic children below the age of 4 years. J Allergy Clin Immunol 1998;101(1 Pt 2)A1052:S253.
49.Foresi A., Pelucchi A., Gherson G., Mastropasqua B., Chiapparino A., Testi R. (1996) Once daily intranasal fluticasone propionate reduces nasal symptoms and inflammation but also attenuates the increase in bronchial hyperresponsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996;98:274-282.
50.Fowler P. D., Gazis A. G., Page S. R., Jones N. S. (2004) A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hyp- othalamo–pituitary–adrenal axis and bone turnover in patients with nasal polyposis.
Abstract Book EAACI Congress June 2004. Assessed in Internet: “j.1398-9995.57. s73.78.x.pdf”.
51.FPCPWG (1994). Fluticasone Propionate Collaborative Pediatric Working Group.
Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. J Pediatr. 1994;125:628-634.
52.Galant S. P. (2003) Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients, 2003 in http:// www.looksmart.com.
53.Gazis A.G., Homer J.J., Henson D.B., Page S.R., Jones N.S. (1999) The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otorhinolaryngol 1999;24:495-498.
54.Grossman J., Banov C., Bronski E.A. et al. (1993) Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics
1993;92:594-599.
55.Grossman J. (1997) One airway, one disease. Chest 1997;111:11S-16S..
56.Gulant S.P., Ahrens R.C., Dockhorn R.J. et al. (1994) Treatment of seasonal allergic rhinitis with once daily intranasal fluticasone propionate therapy in children. J Pediatr
1994;125:628-634.
57.Hallen H. et al. (1997) Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy, 1997; 27: 552-558.
58.Hamilos D.L. et al. (1998) GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin. Exp. Allergy 28, 1145.
59.Hamilos D.L., Thawley S.E., Kramper M. A. et al. (1999) Effect of intranasal fluticasone on cellular inflitration, endothelial adhesion molecule expression and proinflammaory cytokine mRNA in nasal polyp disease. J. Allergy Clin. Immunol., 103, 79-87.
60.Hartwig S., Linen M. et al. (1988) Budesonide nasal spray as prophylactic treatment after polypectomy (A double-blind clinical trial). J Laryngol Ool, 1988; 102, 79-87.
61.Hedman J., Kaprio J. et al. (1999) Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in population-based study. Int
J Epidemiol 1999; 28: 717-722.
62.Hockey P.M. et al. (1998) Airway remodeling and repair. In: Denburg J.A. (edit.): Allergy and Allergic diseases. Totowa, NJ, Humana Press, 567.
63.Holm A.F., Fokkens W.J., Godthelp T., Mulder P.G., Vroom T.M., Rijntjes E. (1998) A
1-year placebo controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial rhinitis: a safety and biopsy study. Clin Otolaryngol 1998;23:69-73.
64.Holmberg K., Juliusson S., Balder B., Smith D.L., Richards D.H., Karlsson G. (1997)
Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann
Allergy Asthma Immunol 1997;78:270-276.
65.Hosemann W., Gode U., Wagner W. (1994) Epidemiology, pathophysiology of nasal polyposis, and spectrum of endonasal sinus surgery. Am J Otolaryngol 1994; 15 (2): 85-98.
66.Howarth P. H. (2000) A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy Volume 55 Issue suppl
62 Page 6 — June 2000.
67.Howland W.Ñ. III. (1996) Fluticasone propionate: topical or systemic effects. Clin Exp Allergy 1996;26:18-22.
68.Hurst D.S.. (1990) Allergy management of refractory serous otitis media. Head Neck Surgery 1990; 102: 664.
69.International Consensus (1994): Position statement on nasal polyps. Rhinology 1994; 32, 126.
70.ISAAC (1998) Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. The international study of asthma and allergies in childhood (ISAAC). Lancet, 1998; 351: 1225-1232.
71.Jankowski R., Bodino C. (2003) Evolution of symptoms associated to nasal polyposis following oral steroid treatment and nasalisation of the ethmoid-radical ethmoidectomy is functional surgery for NPS. Rhinology 41, 211.
72.Javed Sh. (2004) Allergic Rhinitis, March 3, 2004 in “eMedicine.com”.
73.Jordana G., Dolovich J., Briscoe M.P., et al. (1996) Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis.
J Allergy Clin Immunol 1996;97:588 –95.
74.Juliusson S., Holmberg K., Balder B., Smith D.L., Karlsson G. (1996) Fluticasone aqueous nasal spray in the treatment of nasal polyposis. J Allergy Clin Immunol 1996; 97 (1, part 3): 191.
75.Kanai N., Denburg J., Jordana M., Dolovich J. (1994) Nasal polyposis inflammation. Effect of nasal steroid. Am. J. Resp. Crit. Case Med. 150, 1094 –1100.
76.Karlsson G., Juliusson S. et al. (1995) Allergy 1995; 26 (50): 191.
77.Karlsson G., Rundkrantz H. (1982) A randomized trial of intranasal beclometasone dipropionate after polypectomy. Rhinology, 1982; 20, 144-148.
78.Kaszuba S.M. et al. (2001) Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Int
Med 2001; 161: 2581-2587.
79.Keith P., Nieminen J., Hollingworth K. (1998) The efficacy and tolerability of fluticasone propionate (FP) nasal drops 400 mg daily compared with placebo in nasal polyps. Allergy 1998;53 (Suppl 43):165.
80.Keith P.K., Conway R.N., Dolovich J. (1996) Development and validation of nasal polyposis quality of life questionnaire. J Allergy Clin Immunol, 1996, 97, 192.
81.Kele N. (2004) Treatment of Allergic Rhinitis during Pregnancy. American Journal of Rhinology 1 January 2004, vol. 18, no. 1, pp. 23-28(6) .
82.Kiely J.L., Nolan P., McNicholas W.T. (1998) Efficacy of intranasal fluticasone propionate on snoring and sleep apnoea. Am J Respir Crit Care Med 1998;157:A283.
83.Kozma C.M., Schulz R.M., Sclar D.A., Kral K.M., Mackowiak J.I. (1996) A comparison of costs and efficacy of intranasal fluticasone and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996; 18: 334-346 .
84.Larsen K., Tos M. (1994) Clinical course of patients with primary nasal polyposis. Acta Oto-Laryngologica, 114, 556 — 559.
85.Larsen P.L. et al. (1992) The early stage of polyp formation. Laryngoscope, 102, 670677.
86.Larsen P.L., Tos M. (1996) Anatomic site of origin of nasal polyps: endoscopic nasal and paranasal sinus surgery as a screening method for nasal polyps in autopsy material. Am J Rhinol 1996; 10, 211-216.
87.Lau J., Zucker D., Engels E.A., et al. (1999) Diagnosis and treatment of acute bacterial rhinosinusitis. Evidence Report/Technology Assessment no. 9. AHCPR publication no. 99E016. Rockville: Agency for Health Care Policy and Research,Mar 1999
(www.ahcpr.gov/clinic/sinussum.htm).
88.Lemanske R.F. (1998) A review of the current guidelines for allergic rhinitis and asthma. J Allergy Clin Immunol. 1998;101(2):S392-S396.
89.Lildholdt T., Rundkrantz H., Bende M., Larsen K. (1997) Glucocorticoid treatment for nasal polyps. The use of topical budesonide powder, intramuscular budesonide and surgical treatment. Arch Otolaryngol Head Neck Surg 1997;123:595-600.
90.Lildholdt T. (1994) Position statement on nasal polyps. Rhinology 1994; 32: 126.
91.Lildholdt T., Dahl R., Mygind N. (1997) Effect of corticosteroids on polyps. Evidence from controlled trials. In: Nasal Polyposis. An Inflammatory Disease and Its Treatment,
Munksgaard, Copenhagen 1997, 160-169.
92.Lim R. (1998) Clinical practice guideline for the management of sinusitis in family practice. 1998. Assessed in Internet: “Management of Sinusitis in Family Practice.pdf”.
93.Lindqvist N., Balle V.H., Karma P. et al. (1986) Long term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12 month multicentre study. Allergy 19- 86;41:179-186.
94.Lund V. J., Mackay I. S. (1993) Staging in rhinosinusitis. Rhinology, 31, 183.
95.Lund V. (2004) Treating polyposis and chronic rhinosinusitis: the first response. “Responding to challenge of polyposis and rhinosinusitis. EAACI Congress,Amsterdam, June 13, 2004. The abstract book”. p. 8-12.
96.Lund V.J., Aaronson D., Bousquet J., et al. (1994) International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49: suppl 19.
97.Lund V.J., Flood J., Sykes A.P., Richards D.H. (1998) Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998;124:513-518..
98.McDowall J.E., Mackie A.E., Ventresca G.P., Bye A. (1997) The human pharmacokinetics and bioavailability of intranasal fluticasone propionate. Clin Drug Invest 1997;
14:44-52.
99.McNally PA, White MV, Kaliner MA. (1997) Sinusitis in an allergist’s office: analysis of 200 consecutive cases. Allergy Asthma Proc. 1997;18:169-175.
100.Medical News Today, (2004). Intranasal corticosteroid receives FDA pregnancy Category B rating for allergic rhinitis. Assessed in Internet: “Intranasal corticosteroid receives FDA pregnancy Category B rating for allergic rhinitis.htm” .
101.Meltzer E. (1998) An overview of current pharmacotherapy in perrenial rhinitis. J. Allergy Clin. Immunol. 95, 1097.
102.Meltzer E. (2004) Is there a role for intranasal corticosteroids in acute rhinosinusitis? “Responding to challenge of polyposis and rhinosinusitis. EAACI Congress, Amsterdam, June 13, 2004. The abstract book”. p. 16-19.
103.Meltzer E.O. (1994) Eur Resp Review 1994; 4: 266-270.
104.Meltzer E.O., Charous B.L., Busse W.W. et al. (2000) Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The
Nasonex Sinusitis Group. J Allergy Clin Immunol. 2000;106:630-637.
105.Meltzer E.O., Orgel A.H., Backhaus J.W. et al. (1993) Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol 1993;92:8- 12–23.
106.Meltzer E.O., Orgel H.A., Bronshy E.A. et al. (1990) A dose ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990; 86: 221-230.
107.Meltzer E.O., Yalowayski A.A., Orgel H.A., Harris A.G. (1998) Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998;102:339-349.
108.Meltzer E.O. (1997) Allergy. 1997;52(suppl 36):33-40.
109.Minshall E., Ghaffar O., O’Brien F., et al. (1998) Assessment by nasal biopsy of longterm use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648-654.
110.Muller M., Renkawitz R. (1991) The glucocorticoid receptor. Biochem. Piophys. Acta 1008, 171.
111.Mullol J. et al. (1999) Cytokine gene expression and release from epithelial cells. A comparison between healthy mucosa amd nasal polyps. Clin. Exp. Allergy 25, 607.
112.Munk Z.M., LaForce C., Furst J.A., Simpson B., Feiss G., Smith J.A. (1996) Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;77:277-281.
113.Mygind N. (1999) Advanced in the medical treatment of nasal polyps. Allergy 1999 54 suppl. 53, 12-16.
114.Mygind N. (2004) Oral versus Nasal Topical Therapy, and Pharmakokinetics. 2004 Assessed in Internet: “WAO Educational Programs World Allergy Forum.htm”.
115.Mygind N., Bretlan P., Sorensen H. (1974) Scanning electron microscopic studies of nasal polyps. Acta Otolaryngol (Stockh) 1974: 78 436-443.
116.Naclerio R.M., Mackay I.S. (1997) Guidelines for the management of nasal polyposis; In: Nasal Polyposis. Eds Mydind N, Lildholdt T. Copenhagen. Munksgaard, 177-180, 1997.
117.Namazy J., Schatz M., Long L. et al. (2004) Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol. 2004;- 113:427-432.
118.Nash D.B., Sullivan S.D., Mackowiak J. (2000) Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. Am J Managed
Care. 2000;6(suppl):S3-S20.
119.Nathan R.A. (1996) Changing strategies in the treatment of allergic rhinitis. Ann Alerg Astm Immun Vol 77, Oct, 1996, 255-259.
120.Nathan R.A. (2003) Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma
Immunol. 2003;90:182-191.
121.Nayak A.S., Settipane G.A., Pedinoff A. et al. (2002) Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma
Immunol 2002; 89:271-278.
122.Ngamphaiboon J., Thepchatri A., Chatchatee P. et al. (1997) Fluticasone propionate aqueous nasal spray for perennial allergic rhinitis in children. Ann Allergy Asthma
Immunol. 1997;78:479-484.
123.Parikh A., Scadding G.K., Darby Y., Baker R.C. (2001) Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology 2001 Jun; 39(2):75-9.
124.Passalacqua G., Albano M., Canonica G.W. et al. (2000) Inhaled and nasal corticosteroids: safety aspects. Allergy. 2000;55:16-33.
125.Patow C.A., Kaliner M. (1983) Corticosteroid treatment of rhinologic diseases. Ear Nose Throat J 1983;62:14 –27.
126.Pedersen B., Dahl R. et al. (1995) Fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Allergy, 1995; 50, 794-799.
127.Pentilla M., Poulsen P., Hollingworth K., Holmstrom M. (2000) Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 mg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebocontrolled, randomised study in adult patients. Clin Exp Allergy 2000;30:94-102.
128.Penttilä M., Holmström M., Poulsen P., Hollingworth K. (1998) The efficacy and tolerability of fluticasone propionate (FP) nasal drops 400mcg once dialy and twice daily compared with placebo in the treatment of nasal polyposis. Allergy 1998; 53 (Suppl 43): 109.
129.Pipkorn U., Pukander J., Suonpaa J., Makinen G., Lindqvist N. (1988) Long-term safety of budesonide nasal aerosol: a 5.5 year follow-up study. Clin Allergy 1988;18: 253-259.
130.Prenner B.M. (1997) Allergies for all seasons! Allergy Asthma 1997; 6: 8-9.
131.Puhakka T., Makela M.J., Alanen A. et al. (1998) Sinusitis in the common cold. J Allergy Clin Immunol 1998;102:403-408.
132.Pullerits K. et al. (2002) Comparison of treatment with nasal corticosteroid vs leukotriene antagonist in seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:949-55.
133.Qvarnberg Y., Kantola O., Salo J., Toivanen M., Valtonen H., Vuori E. (1992) Influence of topical steroid treatment on maxillary sinusitis. Rhinology 1992;30:103-12.
134.Rachelefsky G.S., Chervinsky P., Meltzer E.O. et al. (1998) An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ) on long-term growth in children. J Allergy Clin Immunol 1998;101:A979.
135.Radenne F., Lamblin C. et al. (1999) Quality of life in nasal polyposis, J Allergy Clin Immunol. 1999; 104, 79-84.
136.Ratner P.H., van Bavel J.H., Martin B.G. et al. (1998) A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998;47:118-125.
137.Rhunno J., Anderson B., Denburg J. (1990) A double-blind comparison of intranasal budesonide with placebo for polyposis. J Allergy Clin Immunol 1990;86:946-953.
138.Richards D.H., Milson C.M. (1996) Fluticasone propionate: a well-tolerated and effective treatment for perennial rhinitis in children aged 4-11 years. Pediatr Allergy
Immunol. 1996;7:35-43.
139.Rodenfeld R.M., Mandel E.M., Bluestone C.D. (1991) Systemic steroids for otitis media with effusion in children. Arch Otolaryngol Head Neck Surg 1991;117:984989.
140.Rowe-Jones J.M., Mackay I.S. (1998) Management of nasal polyps. Curr Opin Otolaryngol Head Neck Surg 1998;6:41-46.
141.Ruhno J., Andersson B., Denburg J. et al. (1990) A double-blind comparison of intranasal budesonide with placebo for nasal polyposis. J Allergy Clin Immunol 1990; 86: 946-953.
142.SAARWG (1996). Allergic rhinitis in South Africa: diagnosis and management Consensus Document: South African Allergic Rhinitis Working Group. S Afr Med J 1996; 86: 1315-1328.
143.Salgo P.L., Casale T.B. (2003) Targeting the allergic cascade: current and evolving options? Medical Crossfire Vol 4, No 2, Feb 2003, 1-17.
144.Scadding G. K. (2000) Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases Allergy 2000: 62: 19-23.
145.Scadding G.K., Parikh A., Baker R.C., Richards D.H. (1998) Chronic rhinosinusitis: effect of fluticasone propionate aqueous nasal spray. J Allergy Clin Immunol 1998;- 101(1 Pt 2)A1045:S252.
146.Schenkel E.J., Skoner D.P. et al. (2000) After One Year of Treatment With Mometasone Furoate Aqueous Nasal Spray Absence of Growth Retardation in Children With Perennial Allergic Rhinitis. Pediatrics 2000;105;22-29.
147.Schwartz R.H., Schwartz D.M., Grundfast K.M. (1980) Intranasal beclomethasone in the treatment of middle ear effusion: a pilot study. Ann Allergy 1980;45:284-287.
148.Settipane G., Korenblat P.E., Winder J. et al. (1995) Triamcinolone acetonide aqueous nasal spray in patients with seasonal ragweed allergic rhinitis: a placebo-controlled, double-blind study. Clin Ther 1995;2:252-263.
149.Settipane G.A., Chaffe F.H. (1977) Nasal polyps in asthma and rhinitis: a review of 6,037 cases. J Allergy Clin Immunol 1977;59:17-21.
150.Settipane R.J., Hagy G.W., Settipane G.A. (1998) Long-term risk factors for developing asthma and allergic rhinitis: a 23 year follow up of college students. Allergy and Asthma Proceedings 1998;19: 185-188.
151.Shapiro G.G., Rachelefsky G.S. (1992) Introduction and definition of sinusitis. J Allergy Clin Immunol 1992;90:417– 418.
152.Shikani A. H. (1999) Sinusitis: A Head and Neck Surgeon’s Perspective, 1999 In: www.medscape.com/viewarticle/408719 .
153.Simons F.E.R. (1989) H1-receptor antagonists: Clinical pharmacology and therapeutics. J Allergy Clin Immunol 1989;84: 845–61.
154.Simpson R.J. (1994) Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994; 73: 497-502. .
155.Skoner D.P., Angelini B.J., Gentile D.A. et al. (2004) The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. (в друку 2004).
156.Soderberg-Warner M.L. (1984) Nasal septum perforation associated with topical corticosteroid therapy. J Pediatr 1984; 105, 840-841.
157.Spector S.L., Bernstein I.L., Li J.T., Berger W.E., Kaliner M.A., Schuller D.E. et al. (1998) Parameters for the diagnosis and management of sinusitis. J Allergy Clin Immunol 1998; 102:S107–S144.
158.Stempel D.A., Thomas M. (1998) Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag
Care. 1998;4(1):89-96.
159.Storms W., Bronsky E., Findlay S. et al. (1991) Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis. Ann Allergy 19- 91;66:329-457.
160.Synnerstad B., Lindqvist N. (1996) A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial nonallergic rhinitis: a 12-month study. Br J Clin Pract 1996;50:363-366.
161.Szefler S. J. (2001) Pharmacokinetics of intranasal corticosteroids. Journal of Allergy & Clinical Immunology, 2001; 108: S26-S31 .
162.Tos M., Drake-Lee A., Lund V.J., Stammberger H. (1989) Treatment of nasal polyps
— medication or surgery. Rhinology 1989; 27: 45-49.
163.Tracy J.M., Demain J.G., Hoffman K.M., Goetz D.W. (1998) Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Ann Allergy Asthma
Immunol 1998;80:198-206.
164.Trangsrud A.J., Whitaker A.L., Small R.E. (2002) Intranasal Corticosteroids for Allergic Rhinitis. Pharmacotherapy 2002 22(11):1458-1467.
165.Tsai M.J., O`malley B.W. (1994) Molecular mechanizm of action of steroid/thyroid receptor superfamily. Ann Rev. Biochem. 63, 451.
166.UMHS (2003) Allergic Rhinitis Patient Education Handout. UMHS Clinical Care Guideline 2003 Clinical Reference Systems.
167.van As A. et al. (1991) Ann Allergy 1991; 67: 156-162.
168.van Camp C., Clement P.A.R. (1994) Results of oral steroid treatment in nasal polyposis. Rhinology 1994; 32: 5-9.
169.van Cauwenberge P. et al. (2000) Consensus statement EAACI on the treatment of allergic rhinitis. Allergy 2000: 55: 116-134.
170.van Cauwenberge P. (2000) Summary. Allergy 2000: 62: 24.
171.van der Baan S. (1997) Epidemiology and natural history. In: Nasal Polyposis. An inflammatory Disease and Its Treatment, Munksgaard, Copenhagen, 1997; 13-16.
172.Vargas R. et al. (1998) Effect of fluticasone propionate aqueous nasal spray versus oral prednisolone on the hypothalamo-pituitary-adrenal axis. J. Allergy Clin. Immunol. 102, 191.
173.Virolainen E., Puhakka H. (1980) The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology 1980; 18: 9- 18.
174.Wald E.R. Sinusitis in children. N Engl J Med 1992;326:319 –23.
175.Wallberg et al. (1999) Histone acethyltransferase complexes can mediate transcriptional activation by the major glucocorticoid receptor activation domain. Mol. Cell. Biol. 37, 9586.
176.Walsh G.M., Wardlaw A.J. (1997) Dexamethasone inhibits prolonged survival and autocrine granulocyt-macrophage colony-stimulating factor production by human eosinophils cultured on laminin or tissue fibronectin. J. Allergy Clin, Immunol. 100, 208.
177.Watson W.T., Becker A.B., Simons F.E. (1993) Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma; effect on lower airway responsiveness. J
Allergy Clin Immunol 1993; 91: 97-100.
178.Webb D.R., Meltzer E.O., Finn A.F. Jr. et al. (2002) Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy
Asthma Immunol. 2002;88:385-390.
179.Weiner J.M., Abramson M.J., Puy R.M. (1998) Intranasal corticosteroids versus oral
H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials BMJ. 1998 Dec 12; 317 (7173): 1624–1629.
180.Welsh P.W., Stricker W.E., Chu C.P. et al. (1987) Efficacy of beclomethasone nasal solution, flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo
Clinic Proc 1987;62:125-134.
181.White A.R., Kaye C., Poupard J. et al. (2004) Augmentin (amoxicillin/clavulanate) in the treatment of community acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004 53 (Suppl) S1, i3 — i20.
182.Wihl J.-Å., Andersson K.-E., Johansson S.-Å. (1997) Systemic effects of two nasally administered glucocorticosteroids. Allergy 1997;52:620-626.
183.Wiseman L.R., Benfield P. (1997) Intranasal fluticasone propionate. A reappraisal of its pharmacological and clinical efficacy in the treatment of rhinitis. Drugs 1997; 53: 885-907.
184.Wolthers O.D., Pedersen S. (1994) Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994;49:96-99.
185.Wolthers O.D., Pedersen S. (1993) Short term growth in children with allergic rhinitis treated with oral antihistamine, intranasal and depot corticosteroids. Acta Pediatr
1993;82:635-640.
186.Wright, A. L. et al. (1994) Epidemiology of physician diagnosed allergic rhinitis in childhood. Pediatrics 1994 94:895-901.
187.Zeiger R.S. (1992) Prospects for ancillary treatment of sinusitis in the 1990s. J Allergy Clin Immunol 1992;90: 478–95.
188.Ильина Н.И., Польнер С.А. (2001) Круглогодичный аллергический ринит. — Consilium Medicum Том 3/N 8/2001.
189.Лопатин С. и др. (2001) Клинические рекомендации по диагностике и лечению аллергического ринита. — Consilium Medicum Том 3/N 9/2001.
190.Ильина Н.И. (2000) Аллергический ринит. — Consilium Medicum Том 2/N 8/2000.
Сведения об авторах
Косаковский Анатолий Лукьянович — доктор медицинских наук (1994), профессор (2001), заслуженный рационализатор Украины (1990), действительный член Международной кадровой академии (ЮНЕСКО) (2000), главный детский отоларинголог МЗО Украины (2004), заведующий кафедрой детской отоларингологии, аудио-
логии и фониатрии КМАПО им. П. Л. Шупика (2002), автор более 230 научных работ, в т. ч. 2 монографий, 7 пособий, 32 изобретений, свыше 150 рацпредложений.
Юрочко Федор Богданович — главный детский отоларинголог ГУЗО Львовской ОГА (2004), член редакционной коллегии журнала „Медицина св³ту” (1999), член
Польского ринологического общества (2004), автор 19 публикаций, соавтор 2 пособий, более 80 переведенных работ (в т. ч. 1 книги), 1 рацпредложения.
Михайлов Алексей Борисович — кандидат медицинских наук (2001), менеджер
торговых марок отдела респираторных и антиинфекционных препаратов предста-
вительства компании GSK в Украине (2003), автор 1 рацпредложения, соавтор 2
пособий, автор 51 публикации.
Учебное издание
Косаковский Анатолий Лукьянович
Юрочко Федор Богданович
Михайлов Алексей Борисович
Эндоназальные
кортикостероиды
Учебное пособие
для студентов и преподавателей
медицинских высших учебных заведений
и врачей
Художественно-технический редактор
Зиновий Матчак
Компьютерная верстка
Мирослав Дуб
Цветоделение и обложка
Ïåòð Êëèì
Формат 70х100/16. Бумага офсетная.
Печать офсетная.
Гарнитура “Прагматика”.
Усл. печат. лист. 3,95. Уч.-изд. лист. 3,46.
Видавництво Мс Львов, 79071, ул Кульпарковская , 131.
Òåë . (0322) 63-34-65
Å-mail: msvitu@mail.lviv.ua